The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Strain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor
Sibilia, M., & Wagner, E. F. (1995) · Science · doi:10.1126/science.7618085 · Cited by 1,002
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
Matrix metalloproteinases in tumor invasion and metastasis
Stamenkovic, I. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0379 · Cited by 815
Specificity within the EGF family/ErbB receptor family signaling network
Riese, D. J., & Stern, D. F. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v · Cited by 809
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Self-citationEpidermal growth factor receptors: critical mediators of multiple receptor pathways
Hackel, P. O., Zwick, E., Prenzel, N., & Ullrich, A. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80024-6 · Cited by 605
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Intermolecular association of the p185 protein and EGF receptor modulates EGF receptor function
Wada, T., Qian, X., & Greene, M. I. (1990) · Cell · doi:10.1016/0092-8674(90)90697-d · Cited by 361
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Gullick, W., Love, S., Wright, C., Barnes, D., Gusterson, B., Harris, A., & Altman, D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.100 · Cited by 327
Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
Bargmann, C. I., & Weinberg, R. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03044.x · Cited by 315
Involvement of pp60c-src with two major signaling pathways in human breast cancer.
Luttrell, D. K., Lee, A., Lansing, T. J., Crosby, R. M., Jung, K. D., Willard, D., Luther, M., Rodriguez, M., Berman, J., & Gilmer, T. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.83 · Cited by 271
ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
Expression of the ERBB3 gene product in breast cancer
Lemoine, N., Barnes, D., Hollywood, D., Hughes, C., Smith, P., Dublin, E., Prigent, S., Gullick, W., & Hurst, H. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.420 · Cited by 234
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
Stern, D. F., & Kamps, M. P. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02906.x · Cited by 222
ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor
Soltoff, T. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550-3558.1994 · Cited by 205
Zabrecky, J. R., Lam, T., McKenzie, S. J., & Carney, W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52354-1 · Cited by 201
Segatto, O., King, C. R., Pierce, J. H., Di Fiore, P. P., & Aaronson, S. A. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.12.5570 · Cited by 186
Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6496 · Cited by 182
Bacus, S. S., Altomare, D. A., Lyass, L., Chin, D. M., Farrell, M. P., Gurova, K. V., Gudkov, A. V., & Testa, J. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205438 · Cited by 157
The type I growth factor receptors in human breast cancer
Rajkumar, T., & Gullick, W. J. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666177 · Cited by 123
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer
Tsai, M.-S., Shamon-Taylor, L. A., Mehmi, I., Tang, C. K., & Lupu, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206130 · Cited by 121
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2
Cockerill, S. G., Stubberfield, C. R., Stables, J. N., Carter, M., Guntrip, S. B., Smith, K., McKeown, S. C., Shaw, R., Topley, P., Thomsen, L. L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00219-0 · Cited by 80
Cited by
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 607
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
Metadata
- Authors
- Xia, W., Liu, L.-H., Ho, P., & Spector, N. L.
- Venue
- Oncogene
- Published
- 2004-01-22
- Volume
- 23
- Issue
- 3
- Pages
- 646-653
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1999513758
- Cited by
- 253
- References
- 37
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.